Genmab — Juli 2015
-
De er konkurrenterne til Genmab da det er dem som har udviklet SAR CD38
-
og licenseret til Sanofi
-
Nasdaq biotech indeks endte op 1,34%.
-
ligner 680 åbning pt
-
684
-
nappede selv 1.000 stk. i dag
-
man vil jo ikke misse toget
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind